| Disease | 26 (81%) SUBJECTS DEVELOPED AMS OVERALL. THIS IS THE FIRST STUDY TO DEMOSTRATE THAT 1 DAY OF PRETREATMENT WITH GINKGO 60 MG TID MAY SIGNIFCANTLY REDUCE THE SEVERITY OF AMS PRIOR TO RAPID ASCENT FROM SEA LEVEL TO 4205 M.
LOWER FOR GINKGO VERSUS PLACEBO (4,RANGE 1-8 VS.5, RANGE 2-9, P-0.03) GINKOG USE DID NOT REACH STATISTICAL SIGNIFICANCE FOR LOWERING INCIDENCE OF AMS COMPARED WITH PLACEBO (GINKGO 7/12, 58.3% VS. PLACEBO 13/14, 92.9%, P=0.07). TWENTY-ONE OF
22-53 YR, RANGE 21-53; 58% VS. 57% CAUCASIAN). TWO (17%) SUBJECTS ON GINKGO AND NINE (64%) ON PLACEBO DEVELOPED SEVERE AMS AND REQUIRED DESCENT FOR THEIR SAFETY (P=0.021); ALL RECOVERED WITHOUT SEQUELAE. MEDIAN LLSR A 4205 M WAS SIGNIFICANTLY
(LLSR) > 3 WITH HAEADACH. SUBJECTS WHO DEVELOPED SEVERE AMS WERE PROMPTLY TRANSPORTED TO LOWER ALTITUDE FOR THE REMAINDER OF THE STUDY. THE GINKGO (N=12) AND PLACEBO )N=14) GROUPS WERE WELL MATCHED (58% VS. 50% FEMALE; MEDIAN AGE 28 YR, RANGE
THE SUMMIT (4205 M) OVER 3 HOURS, INCLUDING 1 HOUR AT 2835 M. THE LAKE LOUISE SELF-REPORT QUESTIONNAIRE CONSTITUTED THE PRIMARY OUTCOME MEASURE AT BASELINE, 2835 M, AND AFTER 4 H AT 4205 M . AMS WAS DEFINED AS A LAKE LOUISE SELF-REPORT SCORE
RAPID ASCENT. IN THIS DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL, 26 PARTICIPATNTS RESIDING AT SEA LEVEL RECEIVED GINKGO (60 MG TID) OR PLACEBO STARTING 25H BEFORE ASCENDING MAUNA KEA, HAWAII. SUBJECTS WERE TRANSPORTED FROM SEA LEVAL TO
PREVIOUS STUDIES SUGGEST THAT 5 DAYS OF PROPHYLACTIC GINKGO DECREASES THE INCIDENCE OF ACUTE MOUNTAIN SICKNESS (AMS) DURING GRADUAL ASCENT. THIS TRAIL WASDESIGNED TO DETERMINE IF GINKGO IS AN EFFECTIVE PROPHYLACTIC AGENT IF BEGUN 1 DAY PRIOR TO |